10月9日早间重要公告一览

Group 1 - Weisheng Information won 5 projects in September with a total amount of 287 million yuan, accounting for 10.45% of the audited revenue for 2024 [1] - Foton Motor's total vehicle sales in September reached 55,300 units, a year-on-year increase of 6.08%, with new energy vehicle sales growing by 47.09% [1] Group 2 - *ST Jianyi plans to terminate the investment cooperation agreement for the monocrystalline silicon project and deregister its subsidiary [2] - Bofei Electric intends to transfer 100% equity of its subsidiary for 38.52 million yuan [3] Group 3 - BYD's new energy vehicle sales in September reached 396,300 units, with a cumulative sales of 3.2601 million units from January to September, a year-on-year increase of 18.64% [4] - Nocera Pharma's subsidiary signed a licensing agreement worth over 2 billion USD for the product Obutin and two preclinical assets [6] Group 4 - Seres reported total sales of 48,286 units in September, an increase of 8.33%, while cumulative sales for the year decreased by 7.79% [8] - BAIC Blue Valley's subsidiary sold 20,539 vehicles in September, a year-on-year increase of 30.15% [9] Group 5 - Huaxin Cement decided to terminate the plan for the overseas subsidiary's spin-off listing due to time constraints and regulatory compliance risks [10] - Huaxin Cement also plans to repurchase shares worth between 32.25 million and 64.5 million yuan [11] Group 6 - Yonghe Co. expects a net profit increase of 211.59% to 225.25% for the first three quarters of 2025 [13] - Runjian Co. won a wind power EPC project worth 1.753 billion yuan [13] Group 7 - Hainan Development plans to apply for bankruptcy liquidation for its subsidiary due to continuous losses and insolvency [14] - Xinjiang Jiaojian won a highway construction project worth 483 million yuan [15] Group 8 - Baili Tianheng's innovative drug BL-ARC001 received approval for clinical trials [16] - Longquan Co. was selected as a candidate for a project worth 50.76 million yuan [18] Group 9 - *ST Gaohong received a notice of termination of listing due to stock price falling below 1 yuan for twenty consecutive trading days [19] - Hainan Huatie's general manager terminated a share reduction plan and plans to increase holdings between 30 million and 50 million yuan [19] Group 10 - OFILM's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [20] - Northeast Pharmaceutical's subsidiary received approval for clinical trials of a CAR-T new drug [21] Group 11 - Huangting International's Shenzhen Huangting Plaza was judicially auctioned to offset debts, contributing 56.03% of the company's total revenue [21]